Citadel Advisors’s Loncar China BioPharma ETF CHNA Stock Holding History

Citadel Advisors’s Portfolio CHNA Stock Details CHNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,621	Closed	-$346K	–	13881
2020 Q4	$346K	Buy	+10,621	New	+$325K	﹤0.01%	8821
2019 Q4	–	Sell	-16,162	Closed	-$347K	–	9953
2019 Q3	$347K	Buy	+16,162	New	+$361K	﹤0.01%	7349

Other funds holding CHNA

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors's CHNA Position: Q1 2021 in Review

Citadel Advisors sold out of Loncar China BioPharma ETF (CHNA) in Q1 2021, closing a stake of 10,621 shares — an estimated $346K sold.

Citadel Advisors first reported a position in CHNA in Q3 2019 and held it in 2 quarters. The position peaked at $347K in Q3 2019. 4 funds tracked by Wall St. Rank hold CHNA as of Q1 2021.

Citadel Advisors reported no remaining Loncar China BioPharma ETF position as of Q1 2021 after selling out during the quarter.
Citadel Advisors sold 10,621 Loncar China BioPharma ETF shares in Q1 2021, an estimated $346K.
Citadel Advisors first reported a position in Loncar China BioPharma ETF in Q3 2019 and held it in 2 quarters.
Citadel Advisors's Loncar China BioPharma ETF position peaked at $347K in Q3 2019.
4 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q1 2021.

Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.